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ABSTRACT
Purpose: To estimate the prevalence of trachoma in suspected-endemic areas of Chad, and
thereby determine whether trachoma is a public health problem requiring intervention.
Methods: We divided the suspected-endemic population living in secure districts into 46 evaluation
units (EUs), and used the standardized methodologies of the Global Trachoma Mapping Project.
A two-stage cluster-sampling procedure was adopted. In each EU, the goal was to examine at least
1019 children aged 1–9 years by recruiting 649 households; all consenting residents aged ≥ 1 year
living in those households were examined. Each participant was examined for trachomatous inflam-
mation—follicular (TF), trachomatous inflammation—intense (TI), and trichiasis.
Results: Two EUs had data that could not be validated, and were excluded from the analysis. GPS
data for three other pairs of EUs suggested that EU divisions were inaccurate; data for each pair
were combined within the pair. In the 41 resulting EUs, 29,924 households in 967 clusters were
visited, and 104,584 people were examined. The age-adjusted EU-level prevalence of TF in
1–9-year-olds ranged from 0.0% to 23.3%, and the age- and gender-adjusted EU-level prevalence
of trichiasis in ≥ 15-year-olds ranged from 0.02% to 1.3%. TF was above the WHO elimination
threshold in 16 EUs (39%) and trichiasis was above the WHO elimination threshold in 29 EUs
(71%). Women had a higher prevalence of trichiasis than did men in 31 EUs (76%). A higher ratio
of trichiasis prevalence in women to trichiasis prevalence in men was associated (p = 0.03) with
a higher prevalence of trichiasis at EU level.
Conclusion: Public health-level interventions against trachoma are needed in Chad. Over 10,000
people need management of their trichiasis; women account for about two-thirds of this total.
The association between a higher ratio of trichiasis prevalence in women to that in men with
higher overall trichiasis prevalence needs further investigation.
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Background
Trachoma, the leading infectious cause of blindness
worldwide,1 is a chronic kerato-conjunctivitis caused
by the bacterium Chlamydia trachomatis.2 Infections,
most commonly occurring in children,3 may lead to
sub-epithelial follicles or more pronounced
inflammation.4 Repeated infection5,6 can lead to scar-
ring of the conjunctivae7 which, when severe enough,
can deform the eyelid and cause eyelashes to touch the
globe (trichiasis).4 Uncorrected trichiasis can result in
corneal abrasion, ulceration, opacification, and poten-
tially, vision loss and blindness.
In 1993, the World Health Organization (WHO)
endorsed the SAFE strategy,8 a comprehensive manage-
ment plan for elimination of trachoma as a public
health problem. SAFE refers to surgery (S) to correct
trichiasis, mass distribution of antibiotics (A) to clear
infection, and facial cleanliness (F) and environmental
improvement (E) to reduce C. trachomatis
transmission.9 To determine whether public health-
level interventions are required, population-based sur-
veys to generate prevalence estimates of trachomatous
inflammation—follicular (TF) and trichiasis are
recommended.10,11
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Chad is a central African country of approximately
12 million people spread across three distinct ecologic
zones: the Sahara Desert, the Sahel, and the Savanna.
Currently the country has a total of 33 ophthalmic
nurses; 35 ophthalmic technicians; and nine ophthal-
mologists (approximately one for every 1.5 million peo-
ple) of whom 5 are in the capital N’Djamena. Though
absolute numbers of eye-care personnel are low, Chad
is fortunate that 90% of them work in the public sec-
tor – specifically in five departments of ophthalmology
(within two secondary and three tertiary hospitals) and
21 secondary eye care units.
A number of population-based trachoma prevalence
surveys were undertaken in Chad in 1984,12 1985,13
200114 and 200415 (Table 1); however, due to financial
constraints, SAFE strategy implementation was not
commenced until 2015. The 1984–2004 surveys
occurred prior to the recent growth in interest in tra-
choma elimination,17 and were conducted at region
level, covering large populations and wide geographical
areas (Table 1). Because of the age and relatively low
resolution of existing data, in order to inform program-
matic action, baseline mapping or re-mapping was felt
to be required.18 We set out to estimate the prevalence
of TF in 1–9-year-olds and the prevalence of trichiasis
in adults in population units of 100,000–250,000 people
in suspected-trachoma-endemic areas of rural Chad.
Materials and methods
Administratively, Chad is divided into 23 regions. Each
region (other than the capital, N’Djamena, which has
a different internal administrative structure) is divided
into two to six health districts, the level at which tra-
choma elimination activities are implemented.19 There
are 61 health districts in total, of which 45 were sus-
pected to have trachoma as a public health problem and
therefore to qualify for mapping, based on criteria
published elsewhere.20 Surveys were conducted in
2014 and 2015. Due to insecurity prevailing at that
time, five suspected-trachoma-endemic health districts
(Bol and Ngouri in Lac Region, Nokou in Kanem
Region, Mandelia in Chari Baguirmi Region and
Bardaï in Tibesti Region) could not be surveyed.
Survey design, field team training and certification,
fieldwork, and data handling were conducted according
to the systems and methodologies of the Global
Trachoma Mapping Project (GTMP).20–23 Each of the
40 secure health districts was generally surveyed as
a single evaluation unit (EU), though six health districts
with populations (estimated using 2009 population cen-
sus data24 and a mean annual population growth rate of
3.6%) significantly larger than the standard 100,000–-
250,000-person EU were divided into two EUs each,
resulting in a total of 46 independent EUs.
Village-level population estimates were provided by
the Division of Health & Information Systems.
According to the 2009 census,24 the proportion of the
population aged 1–9 years was 36% and rural house-
holds had a mean of 5.3 residents. The estimated sam-
ple size requirement per EU was based on an expected
TF prevalence of 10% in children aged 1–9 years,
a design effect of 2.65, and a desire to be 95% confident
of estimating the TF prevalence with ± 3% absolute
Table 1. Findings from trachoma prevalence surveys in Chad, 1984–2004.
Region(s)
surveyed
Year
survey
completed
Estimated
population at time
of survey
Active trachoma
indicator
reported
Number of
0–9-year-olds
examined
Active
trachoma
prevalence in
0–9-year-olds
(%) [95% CI]b
Trichiasis
indicator
reported
Number of
adults
examined
Trichiasis
prevalence in
(%)b Ref
Lac and
Kanem
1984 322,289 F3P3 or F3P2
a 213 30.5 Trichiasis in
≥ 15-year
-olds
256 5.5 12
Ouaddaï and
Biltine
1985 1,558,953 F3P3 or F3P2
a 211 27.5 Trichiasis in
≥ 15-year
-olds
314 3.5 13
Lac, Kanem,
Chari
Baguirmi
2001 1,798,240 TF 2046 33.2
[29.2–37.5]
Trichiasis in
≥ 15-year-old
♀s
1252 1.3 14
Ouaddaï and
Biltine
2001 1,663,512 TF 1906 29.7
[25.6–34.1]
Trichiasis in
≥ 15-year-old
♀s
1240 1.7 14
Moyen Chari 2004 757,127 TF 2409 17.5 Trichiasis in
≥ 15-year-old
♀s
1626 1.4 15
Guéra and
Salamat
2004 1,072,034 TF 2119 26.9 Trichiasis in
≥ 15-year-old
♀s
1605 6.2 15
aIndicators of severe active trachoma in WHO’s 1981 revision of the “FPC” grading system16
bUnadjusted
TF, trachomatous inflammation—follicular; TI, trachomatous inflammation—intense
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precision.22 The resulting sample size (n = 1019) was
increased by 20% to account for non-response; this
resulted in a total of 649 households being required
per EU.
Using a two-stage cluster-sampling design, 22 clusters
(villages or neighbourhoods) were systematically selected
in each EU using probability-proportional-to-population
-size sampling. In each cluster, compact segment
sampling25,26 was then used to select 30 households.
All residents over the age of 12 months who had resided
for at least six months in selected households were
eligible for enrolment.
A survey team consisted of a grader (ophthalmic
technician), a recorder (high school graduate at ease
with Android smart phones and fluent in major local
languages), a local facilitator and a driver. Members of
the survey team underwent standardized GTMP train-
ing, using version 2 of the system.27 Candidate graders
were assessed after training, and only those obtaining
a kappa of ≥ 0.7 for diagnosis of TF in an inter-grader
agreement test with a GTMP-certified grader trainer
were accepted as survey graders. Trachoma grading
was done according to the WHO simplified grading
system.4 Graders used 2.5× magnifying binocular
loupes and sunlight illumination to examine consenting
residents. In eyes diagnosed as having trichiasis, the
presence or absence of trachomatous conjunctival
scarring28,29 was not recorded, so we are unable to
confirm that trichiasis cases detected were due to tra-
choma; consequently, we refer here to the prevalence of
trichiasis instead of the prevalence of trachomatous
trichiasis. Each survey team was trained to ask ques-
tions relating to access to water and sanitation at each
selected household.27
All data were captured electronically, through the
Open Data Kit-based Android phone application pur-
pose-built for the GTMP. Once saved, data were sent to
and stored on the GTMP Cloud-based secure server,
then cleaned and analyzed.22 For each survey cluster,
the proportion of 1–9-year-old children with TF was
adjusted by age in one-year age bands, while the pro-
portion of ≥ 15-year-olds with trichiasis was adjusted
by age and gender in five-year age bands; age and
gender data from the 2009 Chad census were used as
the reference population for this purpose.24 For each
EU, the primary outcome of interest was the age-
adjusted prevalence of TF in 1–9-year-olds; intended
secondary outcomes were the age- and gender-adjusted
prevalence of trichiasis in ≥ 15-year-olds, and house-
hold-level access to water and sanitation. Confidence
intervals for TF and trichiasis prevalence estimates were
calculated by bootstrapping sets of 22 adjusted cluster-
level proportions for each sign, with replacement, over
10,000 replicates, and taking the 2.5th and 97.5th cen-
tiles of the ordered results. Additional gender-specific
age-adjusted estimates of trichiasis prevalence, with
95% confidence intervals, were calculated in analogous
fashion. The ratio of trichiasis prevalence in females to
that in males in each EU was also determined, and
linear regression modelling (Stata 11, College Station
TX, USA) used to generate an intra-class correlation
coefficient, to assess the association between EU-level
trichiasis prevalence and ratio of gender-specific
prevalences.
Ethical clearance was obtained from the Chadian
Ethical Committee for Applied Research, led by the
Ministry of Higher Education; and from the London
School of Hygiene & Tropical Medicine (6319). The
examination procedure was explained to each eligible
adult in the local language and verbal consent for
enrolment and examination was obtained. For eligible
children, verbal consent was obtained from a parent or
guardian. Individuals with active trachoma were offered
1% tetracycline ointment for application into the con-
junctival sac twice-daily for six weeks. Individuals with
trichiasis were offered management by a surgeon.
Results
Fieldwork was undertaken from May 2014 to
November 2015. At a subsequent field team meeting,
it emerged that fieldworkers had considered their main
task to be the acquisition of information on TF and
trichiasis. Contrary to the survey protocol and the
standard GTMP training package, in some villages,
questions about access to water and sanitation had
not been systematically asked in each selected house-
hold. Rather, information had been collected from the
head of the village at the beginning of the day and those
answers used for each household visited. Although this
shortcut was not employed by all teams, it cast doubt
on the accuracy of our water and sanitation data, and
we do not include those data in this manuscript. Data
cleaning revealed inconsistency in definitions of EU
and district boundaries. In particular, in three health
districts (Pala, Béré & Kélo, and Donomanga & Laï)
that had each been split into two EUs, GPS data
revealed considerable overlap between clusters that
had ostensibly been drawn from separate EUs. Data
from these pairs of within-health-district EUs were
therefore combined to re-constitute health-district-
level EUs; the numbers of clusters finally included in
each EU are shown in Table 2. GPS data30 were not
received at all from a high proportion of households
mapped in both of Moundou’s two EUs; those that had
GPS data were geolocated in a pattern inconsistent with
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known administrative divisions. For that reason, the
data from Moundou did not pass GTMP quality con-
trol, and the outputs were, as expected, rejected by the
health ministry. We therefore present data here from
what became a total of 41 surveys.
In total, 104,705 people were enrolled and 104,584
(99%) examined in 29,239 households recruited from
967 clusters (Table 2). There were almost equal num-
bers of 1–9-year-olds (n = 55,885) and ≥ 15-year-olds
(n = 48,699) examined. While the sampling process was
designed to facilitate examination of at least 1,019 chil-
dren in each EU, the survey teams in five EUs did not
reach this target, with the lowest number of 1–9-year-
olds examined in an EU being 956; reports from the
field indicated that in many locations, households had
fewer resident children than expected.
The adjusted TF prevalence in 1–9-year-old children
was ≥ 5% (above theWHO threshold for elimination31) in
16 (39%) of the 41 EUs. Five EUs (12%) had TF preva-
lence estimates of 10–29.9%, and 11 EUs (27%) had TF
prevalence estimates of 5–9.9% (Table 3, Figure 1).
In 12 EUs (29%), the age- and gender-adjusted trichia-
sis prevalence was below the WHO elimination
threshold31 of 0.2% in ≥ 15-year-olds (Table 3, Figure 2).
In the remaining 29 EUs, trichiasis prevalence was ≥ 0.2%.
Two EUs had trichiasis prevalence estimates of > 1%. The
estimated number of trichiasis patients requiringmanage-
ment to achieve elimination of trichiasis as a public health
problem at the time of conclusion of the surveys was
10,562 (Table 3).
Analysis of gender-specific age-adjusted trichiasis pre-
valence estimates revealed mean EU-level prevalences of
0.55% in women and 0.28% in men; in 31 (76%) of the 41
EUs, the prevalence of trichiasis was higher in women
thanmen (Table 4). There were five EUs in which none of
the men examined had trichiasis. The mean ratio of pre-
valence in women to that in men (excluding the five EUs
in which prevalence in men was 0) was 1.70 (SE = 0.53) in
the EUs below the WHO elimination threshold, and 2.31
(SE = 0.48) in the EUs above the WHO elimination
threshold. A higher prevalence of trichiasis was associated
with a greater excess of disease in women (correlation
coefficient = 250, SE = 114, p = 0.03).
Discussion
The results of these and previous surveys demonstrate
that trachoma is a public health problem in Chad. To
move towards elimination of trachoma as a public
health problem, AFE interventions should be imple-
mented for at least three years before re-survey for
the approximately 887,000 people in the five EUs in
which TF prevalence was ≥ 10%, and for at least
one year before re-survey for the nearly 2.8 million
people in the 11 EUs in which TF prevalence was
5–9.9%. Although we are unable to report our own
data on access to water and sanitation, 2017 data
released by the Chad Government and UNICEF suggest
that region-level proportions of the population with
access to potable water are as low as 12% (Ennedi-
Est), and that outside N’Djamena, region-level rates of
open defecation range from 61 to 93%. These condi-
tions are associated with high risk of active
trachoma,32,33 highlighting the need for the F&E com-
ponents of the SAFE strategy here.
The TF prevalence estimates from these GTMP-
supported surveys are considerably lower than those
of previous surveys completed in Chad.13–15 There are
a number of possible explanations for this. When sur-
veys were first planned here, it would have been logical
to choose to start in districts with higher expected
burdens of trachoma – where, in other words, eye
health professionals were already aware of cases.
There may also, or alternatively, have been a temporal
decline in the prevalence of active trachoma in the
intervening period,34–37 with older surveys reflecting
C. trachomatis transmission intensities38 occurring
before more recent improvements in access to water,
sanitation and health care. The GTMP’s emphasis on
standardization of trachoma grading (including grader
training and qualification based on examination of real
people, rather than projected images20) may also have
contributed.
Trichiasis is widespread in Chad (Figure 2), with
more than two-thirds of EUs surveyed in 2014–2015
having trichiasis prevalence estimates above the WHO
elimination threshold. Establishing a public health-level
response to trichiasis throughout the widely dispersed
communities in these EUs will require considerable
capacity building for delivery of high-quality trichiasis
surgery and programme management, as well as com-
munity-based efforts to generate awareness and encou-
rage uptake of services.39,40 The excess burden of
trichiasis among females (Table 4), also noted
elsewhere,25,41,42 compels us to ensure that such efforts
particularly serve women. Experience in other countries
can inform strategies to improve use of eye care ser-
vices by women.43,44 The association noted here
between higher prevalence of trichiasis and greater
ratio of trichiasis prevalence in women to trichiasis
prevalence in men cannot be explained from our data
alone. We note that this was not a pre-specified
hypothesis of the current work, and suggest only that
further investigation is indicated.
Our work has a number of limitations. First, in five
EUs, we did not quite reach the estimated sample size
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requirement. We report confidence intervals here, how-
ever, which facilitates objective assessment of the likely
repeatability of our estimates. In future surveys in Chad,
the sampling approach will be revised slightly to reflect
the smaller-than-expected mean number of children
encountered per household. Second, we recruited these
marginally low numbers of examinees despite what was
apparently an extraordinarily high enrolment rate: 99%
of enumerated residents. We wonder whether field
teams, fearing criticism for incomplete enrolment, may
have failed to register absentees: anecdotally, this
occurred in other constituent projects of the GTMP,
but obtaining definitive proof was difficult.20 Third, this
survey work was commenced prior to the inclusion of
examination for trachomatous conjunctival scarring
(TS4) in standard GTMP protocols,45 as later recom-
mended by a global scientific meeting.29 It is therefore
likely that some of the trichiasis cases included in our
prevalence estimates were due to conditions other than
trachoma28,29; this may explain part of the association
Table 3. Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, prevalence of trichiasis in ≥ 15-year-olds,
backlog of trichiasis cases and number of trichiasis cases needing management to reach the WHO elimination threshold, by
evaluation unit, Global Trachoma Mapping Project, Chad, 2014–2015.
Region
Evaluation unit (label
in Figures 1 and 2)
TF
prevalencea,
% (95% CI)
Trichiasis
prevalenceb, %
(95% CI)
Estimated backlog
of trichiasis casesc
Estimated number of trichiasis cases needing
management to reach WHO elimination threshold
Batha Ati (1) 10.9 (7.3–14.7) 0.57 (0.25–0.98) 774 499
Batha Oum Hadjer (2) 8.6 (6.0–11.7) 0.55 (0.25–0.96) 634 401
Batha Yao (3) 5.4 (3.4–6.8) 0.30 (0.07–0.64) 213 69
Logone
Occidental
Laokassy (4) 2.5 (1.5–3.5) 0.29 (0.07–0.62) 151 45
Logone
Occidental
Bénoye (5) 1.9 (1.1–2.9) 0.02 (0.0–0.05) 21 0
Logone Oriental Doba (6) 5.9 (3.2–9.6) 0.14 (0.0–0.38) 191 0
Logone Oriental Béboto (7) 3.4 (1.4–6.3) 0.15 (0.04–0.30) 102 0
Logone Oriental Bébédjia (8) 1.3 (0.4–2.4) 0.36 (0.10–0.64) 278 122
Logone Oriental Goré (9) 3.4 (1.9–5.2) 0.72 (0.32–1.27 672 483
Logone Oriental Bessao (10) 3.9 (2.0–5.9) 0.92 (0.26–1.66) 1024 799
Mayo Kebbi Est Bongor (11) 2.7 (1.5–4.0) 0.34 (0.0–0.93) 419 170
Mayo Kebbi Est Gounou Gaya (12) 2.4 (1.7–3.0) 0.08 (0.0–0.20) 114 0
Mayo Kebbi Est Guélengdeng (13) 6.0 (2.9–10.1) 0.59 0.23–1.09) 363 238
Mayo Kebbi Est Fianga (14) 1.8 (0.6–3.5) 0.14 (0.0–0.33) 199 0
Mayo Kebbi
Ouest
Pala (15) 6.6 (5.1–8.4) 0.20 (0.07–0.36) 413 0
Mayo Kebbi
Ouest
Léré (16) 4.5 (2.9–5.6) 0.47 (0.09–1.08) 650 370
Tandjilé Béré & Kélo (17) 0.1 (0.0–0.3) 0.06 (0.0–0.16) 104 0
Tandjilé Donomanga & Laï (18) 0.2 (0.0–0.5) 0.50 (0.17–0.94) 646 384
Moyen Chari Sarh (19) 5.1 (3.1–7.4) 0.33 (0.13–0.51) 643 248
Moyen Chari Danamadji (20) 4.3 (2.2–6.2) 0.17 (0.04–0.36) 109 0
Moyen Chari Kyabé (21) 7.3 (5.4–8.9) 0.93 (0.44–1.49) 987 772
N’Djamena Suburbs (22) 4.2 (2.5–6.6) 0.13 (0.0–0.31) 789 0
Borkou Faya (23) 10.1 (4.0–19.0) 1.21 (0.31–2.01) 692 576
Ennédi (West &
East)
Fada & Bahai (24) 8.5 (4.3–14.2) 0.18 (0.0–0.41) 191 0
Bahr El Gazel Moussoro (25) 0.0 (0.0–0.0) 0.60 (0.15–1.25) 956 633
Chari Baguirmi Massenya (26) 4.1 (1.6–6.8) 0.17 (0.04–0.32) 157 0
Chari Baguirmi Dourbali (27) 4.9 (2.2–7.6) 0.52 (0.22–0.92) 497 304
Chari Baguirmi Bousso (28) 7.9 (4.1–14.3) 0.39 (0.15–0.59) 376 181
Hadjer Lamis Massakory (29) 0.1 (0.0–0.2) 0.45 (0.09–0.83) 517 284
Hadjer Lamis Massaguet (30) 0.4 (0.1–0.9) 0.19 (0.05–0.35) 180 0
Kanem Mao-1 (31) 23.3
(19.0–29.4)
0.44 (0.11–0.84) 358 193
Kanem Mao-2 (32) 16.2
(12.7–20.2)
0.23 (0.02–0.50) 173 21
Mandoul Koumra (33) 3.5 (1.8–5.9) 0.87 (0.39–1.32) 1041 799
Mandoul Goundi (34) 11.4 (8.6–15.0) 0.55 (0.31–0.95) 493 311
Mandoul Moïssala (35) 9.8 (7.0–13.8) 0.69 (0.29–1.06) 828 585
Mandoul Bédjondo (36) 0.0 (0.0–0.0) 0.20 (0.0–0.48) 120 0
Wadi Fira Biltine (37) 6.9 (5.4–8.8) 1.30 (0.79–1.86) 1935 1634
Wadi Fira Guéréda (38) 0.3 (0.0–0.6) 0.37 (0.11–0.74) 353 160
Wadi Fira Iriba (39) 1.7 (0.8–2.9) 0.31 (0.09–0.60) 180 62
Hadjer Lamis Bokoro-1 (40) 1.1 (0.2–2.4) 0.55 (0.11–1.19) 347 219
Hadjer Lamis Bokoro-2 (41) 2.0 (0.5–4.8) 0.16 (0.03–0.34) 114 0
Total 19,004 10,562
aAdjusted for age in 1-year age bands (see text)
bAdjusted for gender and age in 5-year age bands (see text)
cBacklog calculated as prevalence × population × proportion of population aged ≥ 15 years (0.494)
dNumber of cases needing management to reach WHO elimination threshold calculated as backlog – (0.002 × population aged ≥ 15 years)
CI, confidence interval
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Figure 1. Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, Global Trachoma Mapping Project, Chad,
2014–2015. Evaluation units are labelled with numbers; the key is found in Tables 2, 3 and 4.
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Figure 2. Prevalence of trichiasis in ≥ 15-year-olds, Global Trachoma Mapping Project, Chad, 2014–2015. Evaluation units are
labelled with numbers; the key is found in Tables 2, 3 and 4.
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between the overall prevalence of trichiasis and the ratio
of gender-specific prevalence estimates. We also did not
ask about previous management of trichiasis, so the
trichiasis prevalence estimates reported here include
both cases known and unknown to the health system.19
These refinements can be helpful in influencing whether
or not public-health-level interventions are needed
against trichiasis.46 Fourth, as noted in the results section,
three EU pairs were combined at the data cleaning stage;
the main implication of this is that the resulting EU
populations (like that for N’Djamena suburbs) are larger
than the recommended 100,000–250,000 people.19 Fifth,
as also already noted, data from two EUs in Moundou,
Logone Occidental Region, could not be approved due to
missing GPS data; as a consequence, results from this EU
are not included in the current report. Sixth, because
household-level questions were not used as set out in
the survey protocol, we are unable to report data on
Table 4. Prevalence of trichiasis in males and females aged ≥ 15 years, by evaluation unit, Global Trachoma Mapping Project, Chad,
2014–2015.
Region
Evaluation
unit
Trichiasis prevalence in all
≥ 15-year-oldsa, % (95% CI)
Trichiasis prevalence in ♀
≥ 15-year-oldsb, % (95% CI)
Trichiasis prevalence in ♂
≥ 15-year-oldsb, % (95% CI)
Ratio of prevalence in
♀: prevalence in ♂s
Batha Ati (1) 0.57 (0.25–0.98) 0.62 (0.17–1.24) 0.50 (0.0–1.19) 1.2
Batha Oum Hadjer
(2)
0.55 (0.25–0.96) 0.54 (0.17–1.13) 0.56 (0.09–1.30) 1.0
Batha Yao (3) 0.30 (0.07–0.64) 0.57 (0.14–1.23) 0 (0.0–0.0) NA
Logone
Occidental
Laokassy (4) 0.29 (0.07–0.62) 0.33 (0.05–0.70) 0.25 (0.0–0.77) 1.3
Logone
Occidental
Bénoye (5) 0.02 (0.0–0.05) 0.03 (0.0–0.10) 0 (0.0–0.0) NA
Logone Oriental Doba (6) 0.14 (0.0–0.38) 0.08 (0.0–0.24) 0.21 (0.0–0.63) 0.4
Logone Oriental Béboto (7) 0.15 (0.04–0.30) 0.08 (0.0–0.19) 0.22 (0.0–0.54) 0.4
Logone Oriental Bébédjia (8) 0.36 (0.10–0.64) 0.30 (0.06–0.52) 0.41 (0.0–1.04) 0.7
Logone Oriental Goré (9) 0.72 (0.32–1.27 1.38 (0.62–2.42) 0 (0.0–0.0) NA
Logone Oriental Bessao (10) 0.92 (0.26–1.66) 1.02 (0.25–1.70) 0.81 (0.0–2.30) 1.6
Mayo Kebbi Est Bongor (11) 0.34 (0.0–0.93) 0.65 (0.0–1.76) 0 (0.0–0.0) NA
Mayo Kebbi Est Gounou Gaya
(12)
0.08 (0.0–0.20) 0.07 (0.0–0.17) 0.10 (0.0–0.29) 0.7
Mayo Kebbi Est Guélengdeng
(13)
0.59 0.23–1.09) 0.89 (0.33–1.67) 0.26 (0.0–0.69) 3.4
Mayo Kebbi Est Fianga (14) 0.14 (0.0–0.33) 0.28 (0.0–0.62) 0 (0.0–0.0) NA
Mayo Kebbi
Ouest
Pala (15) 0.20 (0.07–0.36) 0.12 (0.0–0.28) 0.27 (0.05–0.59) 0.4
Mayo Kebbi
Ouest
Léré (16) 0.47 (0.09–1.08) 0.70 (0.16–1.58) 0.21 (0.0–0.56) 3.3
Tandjilé Béré & Kélo
(17)
0.06 (0.0–0.16) 0.07 (0.0–0.20) 0.06 (0.0–0.17) 1.2
Tandjilé Donomanga
& Laï (18)
0.50 (0.17–0.94) 0.81 (0.22–1.63) 0.16 (0.0–0.43) 5.2
Moyen Chari Sarh (19) 0.33 (0.13–0.51) 0.30 (0.13–0.54) 0.37 (0.0–0.69) 0.8
Moyen Chari Danamadji
(20)
0.17 (0.04–0.36) 0.15 (0.0–0.34) 0.18 (0.0–0.55) 0.8
Moyen Chari Kyabé (21) 0.93 (0.44–1.49) 1.17 (0.61–1.63) 0.67 (0.0–1.53) 1.7
N’Djamena Suburbs (22) 0.13 (0.0–0.31) 0.18 (0.0–0.47) 0.08 (0.0–0.20) 2.4
Borkou Faya (23) 1.21 (0.31–2.01) 2.15 (0.55–3.63) 0.19 (0.0–0.37) 11.6
Ennédi (West &
East)
Fada & Bahai
(24)
0.18 (0.0–0.41) 0.27 (0.0–0.63) 0.09 (0.0–0.26) 3.2
Bahr El Gazel Moussoro (25) 0.60 (0.15–1.25) 0.91 (0.15–2.16) 0.27 (0.0–0.53) 3.4
Chari Baguirmi Massenya (26) 0.17 (0.04–0.32) 0.18 (0.0–0.42) 0.15 (0.0–0.40) 1.2
Chari Baguirmi Dourbali (27) 0.52 (0.22–0.92) 0.68 (0.23–1.31) 0.35 (0.0–0.95) 1.9
Chari Baguirmi Bousso (28) 0.39 (0.15–0.59) 0.41 (0.08–0.67) 0.36 (0.08–0.73) 1.2
Hadjer Lamis Massakory
(29)
0.45 (0.09–0.83) 0.55 (0.09–1.00) 0.35 (0.0–0.89) 1.6
Hadjer Lamis Massaguet
(30)
0.19 (0.05–0.35) 0.26 (0.03–0.58) 0.12 (0.0–0.25) 2.1
Kanem Mao-1 (31) 0.44 (0.11–0.84) 0.51 (0.12–0.89) 0.37 (0.0–1.10) 1.4
Kanem Mao-2 (32) 0.23 (0.02–0.50) 0.16 (0.0–0.39) 0.30 (0.0–0.77) 0.5
Mandoul Koumra (33) 0.87 (0.39–1.32) 0.88 (0.28–1.57) 0.86 (0.14–1.58) 1.0
Mandoul Goundi (34) 0.55 (0.31–0.95) 0.73 (0.32–1.34) 0.35 (0.09–0.68) 2.1
Mandoul Moïssala (35) 0.69 (0.29–1.06) 0.83 (0.23–1.36) 0.54 (0.08–1.25) 1.6
Mandoul Bédjondo (36) 0.20 (0.0–0.48) 0.30 (0.0–0.69) 0.08 (0.0–0.25) 3.6
Wadi Fira Biltine (37) 1.30 (0.79–1.86) 1.64 (0.87–2.83) 0.90 (0.24–1.52) 1.8
Wadi Fira Guéréda (38) 0.37 (0.11–0.74) 0.60 (0.18–1.23) 0.13 (0.0–0.38) 4.8
Wadi Fira Iriba (39) 0.31 (0.09–0.60) 0.40 (0.09–0.88) 0.20 (0.0–0.54) 2.0
Hadjer Lamis Bokoro-1 (40) 0.55 (0.11–1.19) 0.44 (0.16–0.83) 0.67 (0.0–1.76) 0.7
Hadjer Lamis Bokoro-2 (41) 0.16 (0.03–0.34) 0.26 (0.0–0.61) 0.04 (0.0–0.13) 6.2
aAdjusted for gender and age in 5-year age bands (see text)
bAdjusted for age in 5-year age bands (see text)
CI, confidence interval; NA, not applicable
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access to water and sanitation. Though unfortunate, as
much as this situation reveals a weakness in one part of
fieldwork execution, it also demonstrates strength in
fieldwork supervision.
Subsequent to completing these surveys, in addition to
expanding SAFE interventions, the Ministry of Health
commenced planning to re-map Moundou as well as to
undertake mapping in some of, but not all, the EUs in
which surveys were not attempted in 2014–2015.
Undertaking those surveys will contribute to the comple-
tion of nationwide mapping of suspected-trachoma-
endemic areas of Chad, and help chart a course towards
national elimination of trachoma as a public health
problem.47
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